{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:51:06Z","timestamp":1760147466042,"version":"build-2065373602"},"reference-count":57,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In patients with follicular lymphoma (FL), therapeutic advances have led to improved survival, and within this framework, it is important to identify treatment strategies offering a better quality of life. Using (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography (PET\/CT), in patients treated with R-CHOP-like or R-Bendamustine regimens, we assessed changes in the bone mineral density (BMD), musculoskeletal index (SMI), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) at disease onset and at the end of therapy. We evaluated whether the high-steroid regimen could lead to more significant radiological changes than those induced by the steroid-free regimen and whether a low BMD at disease onset is an unfavorable prognostic index. Seventy-nine patients between 60 and 80 years old with a new diagnosis of FL were included in the study. Evaluation of Delta values (pre- and post-therapy mean values) in the two immunochemotherapy regimens showed differences in radiomic parameters within the two patient cohorts. The R-CHOP-like regimen was associated with a significant reduction in BMD, an increase in SAT and VAT, and a reduction in skeletal muscle density (SMD) and SMI. Moreover, patients with high FLIPI showed a BMD below the cut-off value. This study represents the first study demonstrating a prognostic correlation between FLIPI and low BMD.<\/jats:p>","DOI":"10.3390\/cancers15040999","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T05:29:05Z","timestamp":1675661345000},"page":"999","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Body Composition in Patients with Follicular Lymphoma: Asso-Ciations between Changes in Radiomic Parameters in Patients Treated with R-CHOP-like and R-B Regimens: LyRa 01F"],"prefix":"10.3390","volume":"15","author":[{"given":"Fabiana","family":"Esposito","sequence":"first","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosaria","family":"Pascale","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano","family":"Tesei","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7528-398X","authenticated-orcid":false,"given":"Paola Elda","family":"Gigliotti","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Luciano","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Angeloni","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Marinoni","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4369-3321","authenticated-orcid":false,"given":"Federico","family":"Meconi","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"},{"name":"Hematolofy, Fondazione Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Secchi","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Patan\u00e8","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Postorino","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"},{"name":"Hematolofy, Fondazione Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cantonetti","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7659-5392","authenticated-orcid":false,"given":"Guglielmo","family":"Manenti","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, 00133 Rome, Italy"},{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.17116\/patol20198103159","article-title":"Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition): Lymphoid tumors","volume":"81","author":"Polyatskin","year":"2019","journal-title":"Arkhiv Patol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The updated WHO Classification of hematological malignancies. The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.25696","article-title":"Follicular lymphoma: 2020 update on diagnosis and management","volume":"95","author":"Freedman","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Roy","year":"2004","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2352-3026(20)30365-3","article-title":"The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma","volume":"8","author":"Barrington","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1148\/radiol.2019181648","article-title":"Opportunistic osteoporosis screening at routine abdominal and Thoracic CT: Normative L1 trabecular attenuation values in more than 20,000 adults","volume":"291","author":"Jang","year":"2019","journal-title":"Radiology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"20180451","DOI":"10.1259\/bjr.20180451","article-title":"Computed tomography-derived assessments of regional muscle volume: Validating their use as predictors of whole body muscle volume in cancer patients","volume":"91","author":"Halpenny","year":"2018","journal-title":"Br. J. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1017\/S0029665118000046","article-title":"A window beneath the skin: How computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes","volume":"77","author":"Daly","year":"2018","journal-title":"Proc. Nutr. Soc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","article-title":"Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38\/07)","volume":"33","author":"Mamot","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2011-06-359943","article-title":"Interim 18-FDG-PET\/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP","volume":"119","author":"Pregno","year":"2012","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","article-title":"Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"13","author":"Verhoef","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2967\/jnumed.116.180406","article-title":"Baseline total metabolic tumor volume measured with fixed or different adaptive thresholding methods equally predicts outcome in peripheral T cell lymphoma","volume":"58","author":"Cottereau","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: A prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00198-020-05577-9","article-title":"Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures","volume":"32","author":"Bodden","year":"2021","journal-title":"Osteoporos. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1080\/10428190701471973","article-title":"Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures","volume":"48","author":"Cabanillas","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/annonc\/mdt560","article-title":"Alterations in bone mineral density and bone turnover markers in newly diagnosed adults with lymphoma receiving chemotherapy: A 1-year prospective pilot study","volume":"25","author":"Paccou","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/10428194.2016.1233543","article-title":"R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: A single center study of 111 patients","volume":"58","author":"Svendsen","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1097\/HS9.0000000000000303","article-title":"Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin\u2019s Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study","volume":"3","author":"Anargyrou","year":"2019","journal-title":"Hemasphere"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ajh.24465","article-title":"Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy","volume":"91","author":"Xiao","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1200\/JCO.2010.32.7577","article-title":"Transformation of indolent B-cell lymphomas","volume":"29","author":"Montoto","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s12185-011-0822-y","article-title":"High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma","volume":"93","author":"Chihara","year":"2011","journal-title":"Int. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hon.2935","article-title":"Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38\/07 trial post-hoc analysis","volume":"40","author":"Ceriani","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00259-013-2443-6","article-title":"Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET\/CT in patients with extranodal NK\/T-cell lymphoma","volume":"40","author":"Kim","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","article-title":"Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma","volume":"126","author":"Ceriani","year":"2015","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pcad.2010.06.007","article-title":"Mechanisms of anthracycline cardiac injury: Can we identify strategies for cardioprotection?","volume":"53","author":"Sawyer","year":"2010","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","article-title":"Glucocorticoid-induced osteoporosis: An update","volume":"61","author":"Compston","year":"2018","journal-title":"Endocrine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y","article-title":"Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis Results from 394 Patients in the Oslo County Rheumatoid Arthritis Register","volume":"43","author":"Haugeberg","year":"2000","journal-title":"Arthritis Rheumatol."},{"key":"ref_35","first-page":"2582","article-title":"A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis","volume":"27","author":"Sinigaglia","year":"2000","journal-title":"J. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/1529-0131(200010)43:10<2143::AID-ANR1>3.0.CO;2-S","article-title":"Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis","volume":"43","author":"Gravallese","year":"2000","journal-title":"Arthritis Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","article-title":"Activated T cells regulatebone loss and joint destructionin adjuvant arthritis throughosteoprotegerin ligand","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00198-007-0452-7","article-title":"Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: A pilot study","volume":"19","author":"Taxel","year":"2008","journal-title":"Osteoporos. Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"16711","DOI":"10.1073\/pnas.0407335101","article-title":"Postmenopausal osteoporosis, T cells, and immune dysfunction","volume":"101","author":"Teitelbaum","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1074\/jbc.M008198200","article-title":"Tumor necrosis factor-\u03b1 (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways","volume":"276","author":"Zhang","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/ard.2003.008458","article-title":"Joint erosion in rheumatoid arthritis: Interactions between tumour necrosis factor \u03b1, interleukin 1, and receptor activator of nuclear factor \u03baB ligand (RANKL) regulate osteoclasts","volume":"63","author":"Ireland","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389450119666180405094046","article-title":"Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte","volume":"20","author":"Wang","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cyto.2012.08.028","article-title":"Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study","volume":"60","author":"Charbonneau","year":"2012","journal-title":"Cytokine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.clon.2006.01.001","article-title":"Interleukin-6 in Patients with Aggressive and Indolent Non-Hodgkin\u2019s Lymphoma: A Predictor of Prognosis?","volume":"18","author":"Hasan","year":"2006","journal-title":"Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharmthera.2017.02.025","article-title":"Interleukin 32, inflammation and cancer","volume":"174","author":"Hong","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_47","first-page":"47","article-title":"Evaluation of some biochemical markers as prognostic factors in malignant lymphoma","volume":"20","author":"Khalifa","year":"2008","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11764-010-0164-4","article-title":"Polymorphisms in immune function genes and non-Hodgkin lymphoma survival","volume":"6","author":"Zheng","year":"2012","journal-title":"J. Cancer Surviv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"106371","DOI":"10.1016\/j.leukres.2020.106371","article-title":"High serum levels of IL-2R, IL-6, and TNF-\u03b1 are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era","volume":"94","author":"Mozas","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/10428199809057568","article-title":"High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma","volume":"30","author":"Fayad","year":"1998","journal-title":"Leuk. Lymphoma"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.gaitpost.2013.11.014","article-title":"Functional capacity and fear of falling in cancer patients undergoing chemotherapy","volume":"39","author":"Niederer","year":"2014","journal-title":"Gait Posture"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"M211","DOI":"10.1093\/gerona\/50A.4.M211","article-title":"Peripheral Neuropathy: A True Risk Factor for Falls","volume":"50","author":"Richardson","year":"1995","journal-title":"J. Gerontol. Ser. A Biol. Sci. Med. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1210\/jc.2009-0370","article-title":"The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis","volume":"94","author":"Anagnostis","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1097\/MPH.0b013e3181ece2bb","article-title":"Growth in Children with Acute Lymphoblastic Leukemia during Treatment","volume":"32","author":"Collins","year":"2010","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_55","first-page":"435","article-title":"Molecular Control of Immune\/Inflammatory Responses: Interactions between Nuclear Factor-B and Steroid Receptor-Signaling Pathways","volume":"20","author":"Mckay","year":"1999","journal-title":"Endocr. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9550","DOI":"10.1074\/jbc.271.16.9550","article-title":"The human glucocorticoid receptor \u03b2 isoform: Expression, biochemical properties, and putative function","volume":"271","author":"Oakley","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1469-7793.2001.0585a.x","article-title":"Carbohydrate ingestion attenuates the increase in plasma interleukin-6, but not skeletal muscle interleukin-6 mRNA, during exercise in humans","volume":"533","author":"Starkie","year":"2001","journal-title":"J. Physiol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/4\/999\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:24:12Z","timestamp":1760120652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/4\/999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,4]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["cancers15040999"],"URL":"https:\/\/doi.org\/10.3390\/cancers15040999","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2023,2,4]]}}}